New PET Scan to Find Small Bowel Tumors
Part of Cancer clinical trials.
This study tests a special PET/CT scan (68Ga-DOTATOC PET/CT-enterography) to locate neuroendocrine tumors in the small bowel more clearly. It may help identify the exact tumor site before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a neuroendocrine tumor in your small bowel.
- Your tumor can be any grade or growth rate (Ki-67).
- You are a candidate for surgery to remove the tumor.
- You do not have another active cancer at the same time.
- You do not have inflammatory bowel disease (like Crohn's or ulcerative colitis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special PET scan to better evaluate gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It may help your doctor see where the tumors are in your body.
This study uses a PET/CT scan with a small amount of radioactive tracer to see how neuroendocrine tumors are behaving in adults. It may help doctors better detect and evaluate these tumors, especially when symptoms suggest a carcinoid-type hormone problem.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This trial tests a new type of PET/CT scan called [68Ga]Ga-FAPI-04 to see if it can better detect high-grade neuroendocrine tumors. It is for patients whose standard scans show low uptake or who have aggressive tumor features.
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
Hear when a new Neuroendocrine (NE) Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.